<SEC-DOCUMENT>0001999371-25-017964.txt : 20251117
<SEC-HEADER>0001999371-25-017964.hdr.sgml : 20251117
<ACCEPTANCE-DATETIME>20251117070534
ACCESSION NUMBER:		0001999371-25-017964
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20251117
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251117
DATE AS OF CHANGE:		20251117

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tonix Pharmaceuticals Holding Corp.
		CENTRAL INDEX KEY:			0001430306
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				261434750
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36019
		FILM NUMBER:		251489299

	BUSINESS ADDRESS:	
		STREET 1:		26 MAIN STREET, SUITE 101
		CITY:			CHATHAM
		STATE:			NJ
		ZIP:			07928
		BUSINESS PHONE:		212-980-9155

	MAIL ADDRESS:	
		STREET 1:		26 MAIN STREET, SUITE 101
		CITY:			CHATHAM
		STATE:			NJ
		ZIP:			07928

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TAMANDARE EXPLORATIONS INC.
		DATE OF NAME CHANGE:	20080320
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tnxp-8k_111725.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:tnxp="http://tonixpharma.com/20251117">
<head>
     <title>Current Report</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_039_tnxp_tonixpharma.com_20251117 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20251117_20251117 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05B_edei%2D%2DEntityCentralIndexKey_0001430306 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-11-17" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-11-17" id="Fact000004" name="dei:EntityCentralIndexKey">0001430306</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="tnxp-20251117.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-11-17">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001430306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-17</xbrli:startDate>
        <xbrli:endDate>2025-11-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 10pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNITED STATES&#160;</b></p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 1pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FORM <span id="xdx_90D_edei--DocumentType_c20251117__20251117_zqalq85o8GT8"><ix:nonNumeric contextRef="AsOf2025-11-17" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Date of report (date of earliest event reported):
<b><span id="xdx_903_edei--DocumentPeriodEndDate_c20251117__20251117_zI7Pw8P80mSa"><ix:nonNumeric contextRef="AsOf2025-11-17" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">November 17, 2025</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>


<p style="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="xdx_908_edei--EntityRegistrantName_c20251117__20251117_zxVkcMqWNYCb"><ix:nonNumeric contextRef="AsOf2025-11-17" id="Fact000011" name="dei:EntityRegistrantName">TONIX PHARMACEUTICALS HOLDING CORP.</ix:nonNumeric></span></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--EntityIncorporationStateCountryCode_c20251117__20251117_zqsu2227RbGj"><ix:nonNumeric contextRef="AsOf2025-11-17" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityFileNumber_c20251117__20251117_zbd2H63MiNA1"><ix:nonNumeric contextRef="AsOf2025-11-17" id="Fact000013" name="dei:EntityFileNumber">001-36019</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityTaxIdentificationNumber_c20251117__20251117_ztOBJ7Wym6M"><ix:nonNumeric contextRef="AsOf2025-11-17" id="Fact000014" name="dei:EntityTaxIdentificationNumber">26-1434750</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(State or Other Jurisdiction&#160;</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>of Incorporation)&#160;</b></p></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(Commission&#160;</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>File Number)</b></p></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(IRS Employer&#160;</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Identification No.)</b>&#160;</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="xdx_906_edei--EntityAddressAddressLine1_c20251117__20251117_zYkM8d98iJMa"><ix:nonNumeric contextRef="AsOf2025-11-17" id="Fact000015" name="dei:EntityAddressAddressLine1">26 Main Street</ix:nonNumeric></span>, <span id="xdx_90A_edei--EntityAddressCityOrTown_c20251117__20251117_zdHvBmhA0H7h"><ix:nonNumeric contextRef="AsOf2025-11-17" id="Fact000016" name="dei:EntityAddressCityOrTown">Chatham</ix:nonNumeric></span>, <span id="xdx_901_edei--EntityAddressStateOrProvince_c20251117__20251117_zxbXay4KuNJf"><ix:nonNumeric contextRef="AsOf2025-11-17" format="ixt-sec:stateprovnameen" id="Fact000017" name="dei:EntityAddressStateOrProvince">New Jersey</ix:nonNumeric></span>, <span id="xdx_902_edei--EntityAddressPostalZipCode_c20251117__20251117_zmzBbAQQMc1g"><ix:nonNumeric contextRef="AsOf2025-11-17" id="Fact000018" name="dei:EntityAddressPostalZipCode">07928</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Address of principal executive offices) (Zip Code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Registrant&#8217;s telephone number, including area
code: <b><span id="xdx_906_edei--CityAreaCode_c20251117__20251117_zKihTbaNCBsi"><ix:nonNumeric contextRef="AsOf2025-11-17" id="Fact000019" name="dei:CityAreaCode">(862)</ix:nonNumeric></span> <span id="xdx_909_edei--LocalPhoneNumber_c20251117__20251117_zsX5KjV0nlVb"><ix:nonNumeric contextRef="AsOf2025-11-17" id="Fact000020" name="dei:LocalPhoneNumber">799-8599</ix:nonNumeric></span></b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span id="xdx_905_edei--WrittenCommunications_c20251117__20251117_zo65aZr6lF3g"><ix:nonNumeric contextRef="AsOf2025-11-17" format="ixt:booleanfalse" id="Fact000021" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span> Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_901_edei--SolicitingMaterial_c20251117__20251117_zXI2UkJh96xh"><ix:nonNumeric contextRef="AsOf2025-11-17" format="ixt:booleanfalse" id="Fact000022" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span> Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_90C_edei--PreCommencementTenderOffer_c20251117__20251117_z84PqxsHp8ta"><ix:nonNumeric contextRef="AsOf2025-11-17" format="ixt:booleanfalse" id="Fact000023" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span> Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_904_edei--PreCommencementIssuerTenderOffer_c20251117__20251117_zQnk1NLk2aJj"><ix:nonNumeric contextRef="AsOf2025-11-17" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span> Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">Securities registered pursuant
to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 33%; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of each class</span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 34%; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading Symbol(s)</span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 33%; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of each exchange on which registered</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--Security12bTitle_c20251117__20251117_z5fbys5j3Y8e"><ix:nonNumeric contextRef="AsOf2025-11-17" id="Fact000025" name="dei:Security12bTitle">Common Stock</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--TradingSymbol_c20251117__20251117_zysb5KLVoY51"><ix:nonNumeric contextRef="AsOf2025-11-17" id="Fact000026" name="dei:TradingSymbol">TNXP</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The<span id="xdx_907_edei--SecurityExchangeName_c20251117__20251117_zQAIXkfCSS6e"> <ix:nonNumeric contextRef="AsOf2025-11-17" format="ixt-sec:exchnameen" id="Fact000027" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric> </span>Capital Market</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or
Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">Emerging growth company <span id="xdx_900_edei--EntityEmergingGrowthCompany_c20251117__20251117_zD7fz0AdklF4"><ix:nonNumeric contextRef="AsOf2025-11-17" format="ixt:booleanfalse" id="Fact000028" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section&#160;13(a) of the Exchange Act. &#9744;</p>


<!-- Field: Rule-Page --><div style="margin-top: 10pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"></p>


<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 7.01</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 90%"><b>Regulation FD Disclosure.</b></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">On November 17, 2025, Tonix Pharmaceuticals
Holding Corp. (the &#8220;Company&#8221;) announced that TONMYA<sup>TM</sup> (cyclobenzaprine HCl sublingual tablets) is commercially
available at pharmacies by prescription in the United States. A copy of the press release which discusses this matter is furnished hereto
as Exhibit 99.01, and incorporated herein by reference.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">The information in this Item 7.01
of this Current Report on Form&#160;8-K, including Exhibit 99.01 attached hereto, shall not be deemed &#8220;filed&#8221; for purposes
of Section 18 of the United States Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities
of that section, nor shall they be deemed incorporated by reference in any filing under the United States Securities Act of 1933 or the
Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"></p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 10%"><b>Item 8.01.</b></td><td style="width: 90%"><b>Other Events.</b></td></tr>
                                                                                                         </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">On November 17, 2025, the Company announced that TONMYA<sup>TM</sup> is
commercially available at pharmacies by prescription in the United States.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"><i>Forward-Looking Statements</i></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">This Current Report on Form 8-K
contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company&#8217;s product
development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future
results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking
statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate
and management&#8217;s current beliefs and assumptions.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">These statements may be identified
by the use of forward-looking expressions, including, but not limited to, &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221;
&#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221;
&#8220;should,&#8221; &#8220;would&#8221; and similar expressions and the negatives of those terms. These statements relate to future
events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results,
performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the
forward-looking statements. Such factors include those set forth in the Company&#8217;s filings with the SEC. Prospective investors are
cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company
undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%"><b>Item 9.01</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%"><b>Financial Statements and Exhibits.</b></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"></p>


<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 13%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Exhibit</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>No.</b></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 83%; text-align: center"><b>Description.</b></td></tr>
  <tr>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><a href="ex99-01.htm">99.01</a></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><a href="ex99-01.htm">Press Release of the Company, dated November 17, 2025</a></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p></td></tr>
  <tr>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; vertical-align: top"><span style="font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><b>SIGNATURE</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirement of
the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="3"><b>TONIX PHARMACEUTICALS HOLDING CORP.</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 52%">Date: November 17, 2025</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&#160; </span></td>
    <td style="border-bottom: black 1pt solid; width: 24%">/s/ Bradley Saenger</td>
    <td style="width: 23%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bradley Saenger</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>

    <!-- Field: /Page -->





<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjVsKwkAMRVfQPYT5Fvvwhf20qIhVpIj4O9hUBttJyYy1LsldOm0RQyAk954bIUZiSxtVIsN1laVwxqoupUXIsEBGfUPnSHb7GNzM8K6MZaltv/7AhByDjpmPJ9Lde2ejDOYxhKEfTv1oBsEijpZwOgiv0xPShcpRWyVLkDqHE1PNCq3k95Bwli1pqt79pwuyUaRd3DgY5A9EQRjBkRr5In4YSNNEeKO+PLFletbOtW4t6o6EdYmVe2cG+t/eF87fSmI= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.01
<SEQUENCE>2
<FILENAME>ex99-01.htm
<DESCRIPTION>PRESS RELEASE OF THE COMPANY, DATED NOVEMBER 4, 2025
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt"><B><A HREF="tnxp-8k_111725.htm">TONIX PHARMACEUTICALS HOLDING CORP 8-K</A></B></P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: right; margin: 0pt"><B>Exhibit 99.01</B></P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; text-align: left; color: #2573BA; margin-top: 12pt; margin-bottom: 0"><IMG SRC="tonix.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; text-align: center; color: #2573BA; margin-top: 12pt; margin-bottom: 0">Tonix Pharmaceuticals
Announces U.S. Commercial Availability of TONMYA<SUP>TM </SUP>(cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia
Treatment</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><I>TONMYA is now
available by prescription and available for pharmacy ordering nationwide</I></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><I>TONMYA is the
first FDA-approved treatment for fibromyalgia in more than 15 years</I></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><I>TONMYA is a unique,
non-opioid, once-daily bedtime analgesic that significantly reduces fibromyalgia pain and is generally well-tolerated</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">CHATHAM, N.J., November 17, 2025 (GLOBE
NEWSWIRE) --Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (&ldquo;Tonix&rdquo; or the &ldquo;Company&rdquo;), a fully integrated,
commercial biotechnology company, announced today that TONMYA<SUP>TM</SUP> (cyclobenzaprine HCl sublingual tablets) is now commercially
available at pharmacies by prescription in the United States. TONMYA is a first-in-class treatment for fibromyalgia in adults as a non-opioid
analgesic taken once daily at bedtime.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">&quot;The availability of TONMYA is
a momentous day for Tonix, providing the estimated 10 million people living with fibromyalgia a novel treatment that has been shown to
address the debilitating, core symptom of this disease, widespread pain,&rdquo; said Seth Lederman, M.D., Chief Executive Officer of Tonix
Pharmaceuticals. &ldquo;After more than 15 years without innovation for this disease, we are honored to bring this new treatment option
to patients in partnership with the full fibromyalgia community including researchers, patients, and investigators. We are excited and
motivated to make TONMYA accessible to as many patients as possible.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">The latest Phase 3 trial,
RESILIENT, was published&nbsp;in&nbsp;<I>Pain
Medicine</I>&nbsp;with data on primary endpoints measuring pain, and secondary endpoints measuring patient&rsquo;s global impression of
change, patient-reported symptoms and function, sleep disturbance, and fatigue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">&ldquo;For years, fibromyalgia patients
have struggled with limited treatment options that often fall short. The availability of TONMYA marks a meaningful advancement by targeting
neurotransmitters thought to be involved in fibromyalgia,&rdquo; said Andrea L. Chadwick, M.D., MSc, FASA, Anesthesiology, Pain, and Perioperative
Medicine at The University of Kansas Health System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">&quot;We&rsquo;re truly excited about
this new option for people living with fibromyalgia,&quot; said Sharon Waldrop, a person with lived experience and founder of the Fibromyalgia
Association. &quot;The availability of TONMYA provides new hope for our community and represents a crucial step forward in fibromyalgia
treatment.&quot;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">TONMYA was approved by the FDA on August
15, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">The approval incorporated efficacy from
two double-blind, randomized, placebo-controlled, Phase 3 clinical trials of nearly 1,000 patients in total that evaluated TONMYA as a
bedtime treatment for fibromyalgia. Across both Phase 3 trials, TONMYA significantly reduced daily pain scores compared to placebo at
14 weeks, the primary endpoint. Additionally, a greater percentage of study participants taking TONMYA experienced a clinically meaningful
(&ge;30%) improvement in their pain after three months, compared to placebo.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">Across three Phase 3 clinical trials
with over 1,400 patients evaluated, TONMYA was generally well tolerated. The most common adverse events (incidence &ge;2% and at a higher
incidence in TONMYA-treated patients compared to placebo-treated patients) included oral hypoesthesia (numbness in the mouth), oral discomfort,
abnormal product taste, somnolence (drowsiness), oral paresthesia (tingling, pricking or burning in the mouth), oral pain, fatigue, dry
mouth, and aphthous ulcer (canker sore).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"><B>For more information, visit TonmyaHCP.com</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"><B>About Fibromyalgia</B> Fibromyalgia is a chronic pain disorder
that is understood to result from amplified sensory and pain signaling within the central nervous system. Fibromyalgia afflicts an estimated
10 million adults in the U.S., approximately 80% of whom are women. Symptoms of fibromyalgia include chronic widespread pain, nonrestorative
sleep (waking up tired and unrefreshed), fatigue, and morning stiffness. Other associated symptoms include cognitive dysfunction and
mood disturbances, including anxiety and depression. Individuals suffering from fibromyalgia struggle with their daily activities, have
impaired quality of life, and frequently are disabled. Patients with fibromyalgia have double the medical costs compared to the general
population in the U.S.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"><B>About
TONMYA<SUP>TM</SUP> (cyclobenzaprine HCl sublingual tablets)</B>
TONMYA, which was investigated as TNX-102 SL, is a patented sublingual tablet
formulation of cyclobenzaprine hydrochloride, which provides rapid transmucosal absorption and reduced production of a long half-life
active metabolite, norcyclobenzaprine, due to bypass of first-pass hepatic metabolism. As a tertiary amine tricyclic (TAT) and multifunctional
agent with potent binding and antagonist activities at the 5-HT<SUB>2A</SUB> serotonergic, &alpha;1-adrenergic,
H1-histaminergic, and M1-muscarinic receptors, TONMYA is now commercially available as a once-daily bedtime treatment for fibromyalgia
in adults. The United States Patent and Trademark Office (USPTO) issued United States Patent No. 9636408 in May 2017, Patent No. 9956188
in May 2018, Patent No. 10117936 in November 2018, Patent No. 10357465 in July 2019, and Patent No. 10736859 in August 2020. The Protectic&trade;
protective eutectic and Angstro-Technology&trade; formulation claimed in the patent are important elements of Tonix&rsquo;s proprietary
composition. These patents are expected to provide TONMYA with U.S. market exclusivity until 2034. Pending patent applications related
to method of use could extend exclusivity until 2044.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"><B>About the Phase 3 Clinical Trials: RELIEF
and RESILIENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 0">The RELIEF and RESILIENT studies were double-blind, randomized,
placebo-controlled trials designed to evaluate the efficacy and safety of TONMYA<SUP>TM</SUP> (cyclobenzaprine hydrochloride sublingual
tablets) for the treatment of fibromyalgia. RELIEF and RESILIENT were two-arm trials that enrolled 503 and 457 adults with fibromyalgia
across 40 and 33 United States sites, respectively. In both trials, the first two weeks of treatment consisted of a run-in period in
which participants started on TONMYA 2.8 mg (1 tablet) or placebo. Thereafter, all participants increased their dose to TONMYA 5.6 mg
(2 x 2.8 mg tablets) or two placebo tablets for the remaining 12 weeks. The primary endpoint across both trials was the daily diary pain
intensity score change (TONMYA 5.6 mg vs. placebo) from baseline to Week 14 (using the weekly averages of the daily numerical rating
scale scores). Additional details on RELIEF (NCT04172831) and RESILIENT (NCT05273749) are available on clinicaltrials.gov.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">RALLY was a replicate Phase 3 trial to RELIEF and RESILIENT that
demonstrated greater but non-significant treatment effect with TONMYA compared to placebo and demonstrated consistent safety. Results
of this trial may not have been generalizable due to the presence of factors outside the conduct of the study. Additional details are
available on clinicaltrials.gov (NCT04508621).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"><B>Tonix Pharmaceuticals Holding Corp.</B>
Tonix is a fully integrated, commercial-stage biotechnology company. Tonix&rsquo;s development portfolio is focused on central nervous
system (CNS) disorders, immunology, immuno-oncology, infectious and rare diseases. Tonix owns and operates a state-of-the art infectious
disease research facility in Frederick, MD. Tonix Medicines, Inc., a wholly owned commercial subsidiary, markets treatments for fibromyalgia
and acute migraine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">This press release and
further information about Tonix can be found at www.tonixpharma.com.
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"><B>Forward Looking Statements</B> Certain statements in this press
release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified
by the use of forward-looking words such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;forecast,&rdquo; &ldquo;estimate,&rdquo;
&ldquo;expect,&rdquo; and &ldquo;intend,&rdquo; among others. These forward-looking statements are based on Tonix's current expectations
and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those
indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to successfully
launch and commercialize TONMYA and any of our approved products; risks related to the failure to obtain FDA clearances or approvals
and noncompliance with FDA regulations; risks related to the timing and progress of clinical development of our product candidates; our
need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement;
limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under
development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not
undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual
Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;)
on March 18, 2025, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are
expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the
date thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"><B>Investor
Contacts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B>
Mary Ann Ondish</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">
Tonix Pharmaceuticals </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(862) 799-8599 </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">investor.relations@tonixpharma.com<BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"><B>Brian Korb</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">
astr partners</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">
(917) 653-5122

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">brian.korb@astrpartners.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"><B>Media
Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Meagen Hagans</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Weber Shandwick</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(757)358-2033</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">MHagans@webershandwick.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"></P>



<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"><B>INDICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B>
TONMYA is indicated for the treatment of fibromyalgia in adults.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"><B>IMPORTANT SAFETY INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"><B>CONTRAINDICATIONS</B><BR>
TONMYA is contraindicated:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: center; width: 5%"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="width: 95%">In patients with hypersensitivity to cyclobenzaprine or any inactive ingredient in TONMYA.
Hypersensitivity reactions may manifest as an anaphylactic reaction, urticaria, facial and/or tongue swelling, or pruritus. Discontinue
TONMYA if a hypersensitivity reaction is suspected.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: center; width: 5%"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="width: 95%">With concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after discontinuation
of an MAO inhibitor. Hyperpyretic crisis seizures and deaths have occurred in patients who received cyclobenzaprine (or structurally similar
tricyclic antidepressants) concomitantly with MAO inhibitors drugs.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: center; width: 5%"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="width: 95%">During the acute recovery phase of myocardial infarction, and in patients with arrhythmias,
heart block or conduction disturbances, or congestive heart failure.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: center; width: 5%"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="width: 95%">In patients with hyperthyroidism.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"><B>WARNINGS AND PRECAUTIONS</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: center; width: 5%"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="width: 95%"><B>Embryofetal toxicity:</B> Based on animal data, TONMYA may cause neural tube defects when
used two weeks prior to conception and during the first trimester of pregnancy. Advise females of reproductive potential of the potential
risk and to use effective contraception during treatment and for two weeks after the final dose. Perform a pregnancy test prior to initiation
of treatment with TONMYA to exclude use of TONMYA during the first trimester of pregnancy.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: center; width: 5%"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="width: 95%"><B>Serotonin syndrome:</B> Concomitant use of TONMYA with selective serotonin reuptake inhibitors
(SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, tramadol, bupropion, meperidine, verapamil,
or MAO inhibitors increases the risk of serotonin syndrome, a potentially life-threatening condition. Serotonin syndrome symptoms may
include mental status changes, autonomic instability, neuromuscular abnormalities, and/or gastrointestinal symptoms. Treatment with TONMYA
and any concomitant serotonergic agent should be discontinued immediately if serotonin syndrome symptoms occur and supportive symptomatic
treatment should be initiated. If concomitant treatment with TONMYA and other serotonergic drugs is clinically warranted, careful observation
is advised, particularly during treatment initiation or dosage increases. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: center; width: 5%"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="width: 95%"><B>Tricyclic antidepressant-like adverse reactions:</B> Cyclobenzaprine is structurally related
to TCAs. TCAs have been reported to produce arrhythmias, sinus tachycardia, prolongation of the conduction time leading to myocardial
infarction and stroke. If clinically significant central nervous system (CNS) symptoms develop, consider discontinuation of TONMYA. Caution
should be used when TCAs are given to patients with a history of seizure disorder, because TCAs may lower the seizure threshold. Patients
with a history of seizures should be monitored during TCA use to identify recurrence of seizures or an increase in the frequency of seizures.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: center; width: 5%"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="width: 95%"><B>Atropine-like effects:</B> Use with caution in patients with a history of urinary retention,
angle-closure glaucoma, increased intraocular pressure, and in patients taking anticholinergic drugs.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: center; width: 5%"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="width: 95%"><B>CNS depression and risk of operating a motor vehicle or hazardous machinery:</B> TONMYA
monotherapy may cause CNS depression. Concomitant use of TONMYA with alcohol, barbiturates, or other CNS depressants may increase the
risk of CNS depression. Advise patients not to operate a motor vehicle or dangerous machinery until they are reasonably certain that TONMYA
therapy will not adversely affect their ability to engage in such activities.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: center; width: 5%"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="width: 95%"><B>Oral mucosal adverse reactions:</B> In clinical studies with TONMYA, oral mucosal adverse
reactions occurred more frequently in patients treated with TONMYA compared to placebo. Advise patients to moisten the mouth with sips
of water before administration of TONMYA to reduce the risk of oral sensory changes (hypoesthesia). Consider discontinuation of TONMYA
if severe reactions occur.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"><B>ADVERSE REACTIONS</B>
The most common adverse reactions (incidence &ge;2% and at a higher incidence in TONMYA-treated patients compared to placebo-treated patients)
were oral hypoesthesia, oral discomfort, abnormal product taste, somnolence, oral paresthesia, oral pain, fatigue, dry mouth, and aphthous
ulcer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"><B>DRUG INTERACTIONS </B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: center; width: 5%"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="width: 95%">MAO inhibitors: Life-threatening interactions may occur.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: center; width: 5%"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="width: 95%">Other serotonergic drugs: Serotonin syndrome has been reported.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: center; width: 5%"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="width: 95%">CNS depressants: CNS depressant effects of alcohol, barbiturates, and other CNS depressants
may be enhanced.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: center; width: 5%"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="width: 95%">Tramadol: Seizure risk may be enhanced.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: center; width: 5%"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="width: 95%">Guanethidine or other similar acting drugs: The antihypertensive action of these drugs may
be blocked.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"><B>USE IN SPECIFIC POPULATIONS</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: center; width: 5%"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="width: 95%"><B>Pregnancy:</B> Based on animal data, TONMYA may cause fetal harm when administered to a
pregnant woman. The limited amount of available observational data on oral cyclobenzaprine use in pregnancy is of insufficient quality
to inform a TONMYA-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Advise pregnant women about
the potential risk to the fetus with maternal exposure to TONMYA and to avoid use of TONMYA two weeks prior to conception and through
the first trimester of pregnancy. Report pregnancies to Tonix Medicines, Inc., adverse-event reporting line at 1-888-869-7633 (1-888-TNXPMED).</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: center; width: 5%"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="width: 95%"><B>Lactation:</B> A small number of published cases report the transfer of cyclobenzaprine
into human milk in low amounts, but these data cannot be confirmed. There are no data on the effects of cyclobenzaprine on a breastfed
infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the
mother&rsquo;s clinical need for TONMYA and any potential adverse effects on the breastfed child from TONMYA or from the underlying maternal
condition.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: center; width: 5%"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="width: 95%"><B>Pediatric use:</B> The safety and effectiveness of TONMYA have not been established.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: center; width: 5%"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="width: 95%"><B>Geriatric patients:</B> Of the total number of TONMYA-treated patients in the clinical trials
in adult patients with fibromyalgia, none were 65 years of age and older. Clinical trials of TONMYA did not include sufficient numbers
of patients 65 years of age and older to determine whether they respond differently from younger adult patients.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: center; width: 5%"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="width: 95%"><B>Hepatic impairment:</B> The recommended dosage of TONMYA in patients with mild hepatic impairment
(HI) (Child Pugh A) is 2.8 mg once daily at bedtime, lower than the recommended dosage in patients with normal hepatic function. The use
of TONMYA is not recommended in patients with moderate HI (Child Pugh B) or severe HI (Child Pugh C). Cyclobenzaprine exposure (AUC) was
increased in patients with mild HI and moderate HI compared to subjects with normal hepatic function, which may increase the risk of TONMYA-associated
adverse reactions.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">Please see additional safety information in the full
Prescribing Information.
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">To report
suspected adverse reactions, contact Tonix Medicines, Inc. at 1-888-869-7633, or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</P>


<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 12pt 0 0"><IMG SRC="tonix.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 12pt 0 0">Source: Tonix Pharmaceuticals Holding
Corp.</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 12pt 0 0"><I>Released November 17, 2025</I></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>

    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>tnxp-20251117.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +6spw7xRiXhun8uCbn1MSamJ+bP9w5dzuelBtm9yHTlqjy8pY1GaVSRFSg42kZUO -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:tnxp="http://tonixpharma.com/20251117" elementFormDefault="qualified" targetNamespace="http://tonixpharma.com/20251117">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://tonixpharma.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="tnxp-20251117_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="tnxp-20251117_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>tnxp-20251117_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>tnxp-20251117_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20251117.xsd#Cover" roleURI="http://tonixpharma.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tonix.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tonix.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  ^ ),# 2(  A$! Q$!_\0
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MO\M=TZ%"&58BKAWI+4\^A6Q%3,Z%/$[QT/6O^"CTA^R^$64;B'DP/7D5H?\
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M3YEO+K5XUO;F?()#,,[/^ Y->]QL3N+<X/6OSC_8U_:)_P"%>:[%X3UR^/\
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MW)Y  &>]>BF8(C-(%6-3M#.:GCV@$CH:O$9G5Q5-4JNK7WBP^5TL'5]K2V
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?3WW$]35F)"@(( R<\>O>IMK<?2W0<% HIU%,5D?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 17, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 17,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TONIX PHARMACEUTICALS HOLDING CORP.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001430306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-1434750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">26 Main Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Chatham<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(862)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">799-8599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TNXP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tnxp-8k_111725.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tonixpharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>tnxp-20251117.xsd</File>
    <File>tnxp-20251117_lab.xml</File>
    <File>tnxp-20251117_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tnxp-8k_111725.htm">tnxp-8k_111725.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tnxp-8k_111725.htm": {
   "nsprefix": "tnxp",
   "nsuri": "http://tonixpharma.com/20251117",
   "dts": {
    "schema": {
     "local": [
      "tnxp-20251117.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "tnxp-20251117_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tnxp-20251117_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tnxp-8k_111725.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://tonixpharma.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-11-17",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tnxp-8k_111725.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-11-17",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tnxp-8k_111725.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://tonixpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001999371-25-017964-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001999371-25-017964-xbrl.zip
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M=Z1]DZ'<Z4M+PVZ'UG<<5BUQ?+[A!LB8XR\V_."!B]#T!6XT^K!OC@]=#S8
M*M.DE XF0-DS89*<)MB3I'$J0K(\Y?$A::? VV(YPQ(3@V<Z&4,J$-2Y+.1?
M\F^8XG8+)I<*"(,G%1VI\<'(22\?#=T"5P5 "1Z &15M@W LF;X%J%!O \FC
M1TZUQ[ W9GCE BL(:G,):T<+3F;:K4,,A+7DZTJYF/$-ACXG,R!FZA(V*I^N
M:7B'S9=!_)J&WT#DL:E>O7[=W=][_7I=HX:6X3VQ_'0%?UT"A0?OK]_] ;CP
M/9QWK'Y*LM$:=QCN#B%GU<.]ME$W7O=?;:J7>SO=O?[VMEK#F",NO_<9R_\K
M2784F\:#-;.:X8Y7:=0:V7VN6<53)][$B]?%[$^:MOP&YEG:?]>E/*_V7FWN
M[.UWM[=V=M:U>K/NO]Z1XMP1_ ?L8)4Y^GH-9N>I!O-4@_F#:S#K<_071Z>'
M@^'IY<4?X>#KXGT=#WZS+E$?+5M[LI8+/K^ZO!X.+H;J9O#A>/BS.KWX<'E]
MOE86+$QX>'DQO![4?+Z16<29U^R1LI%7,>E-1<5ODNI[HKO&LZ=?E7OZYH:<
MKSH*:VG;XW4"'R[)_L9] F-O%D;S-VQ"&R41=.-/_?T=Z 8??&=4Y)X6O>90
MIW'=ORF(?SKGD0NI<)AR/ *FY>(90X&864G;BP.0G\$UV^Y:LRF]=NMD>2@(
MK&_: IB2 B/#,0]C>=*.Y\5>.IU'GK1*N"<[JA1> 61T)!UJ L(75($DGI0(
M+-GL*EV<+#EE#(Y*1 5';!9% !N7NA835KCNK<]-12G*R]RT0_3NFY4G:?JV
M-'VB!/F2I FE2<4F&&=)G)B6JN1+&# )NG$^8 =0+%<U2,$C<TG0_B[/EN8V
MV@RJC?3,,4?6*1'(#B[KMWM*1"V=9YK"XR. Y&;J\-<RTR[IX173W%1C$E^2
M?X$Y)>F$?YI(UY2<,5H6^ U0QY9%ORA-AW4>@D,>^UBK%C&F2VPKI">-S@T^
ML">;K%F@.E=!5D[R)U%[E*@=E9DKG9HJ!3:/63/)2UFIFR>P'$$H)SC&7F8M
MBCG&NF3VO"R;SHOI+/3R3KLUU:S-C*($X#')7 &.1F*Q(=9\-V%&&W)EWK)I
MS:=M7:,_*J;S+ D#-FJN9NL:X<:GP?4%MN%&#2Z.U-7U\>'@8XTZGE#%=^TB
M;^&9C;)Y,M9R;@E6WX>O?2.5LO>N% /_SQ,</#7=J8_JSFV]A.=P^6XY8I*8
M55(::0T/(*7<NI\%)EK@@!A<73<4![6%L"TP&?E;F#H-#/6$.7NII$L6>*Q!
MC<F_\X2GZ4*&6INN7EH16Y*K/FBW)%7)R9A6SK7M*^!;!I Z>APM%60W1U>S
MQC+JY"J+"9$TPK"W,I,*GU<3K.0$>[7JD W\M6^LIV@V-[!UZHMI^;<NV7[Q
MO4QZLF:/U(,;T]'-//0\#A"C::,%A_=14K/O-M>1%:2\&B#392H5C1I"M%L;
M-S?7ISS@5#_'*R-2P)9T*N!EQ6MJX^;"O/4@?N%7WLP+DHAE1+84B_.<:98+
M FFQ9ZM22M; 8T(6E\"-:^S*ZTH)3_;=8X><\G8:!:#$+O\N3\:Q;$;9I/>U
MY:?[S*R/M,!RR#DU$7(J@!S*]A -V!8MWF!1XFUPW0=U^,Z< .^(J4G8/5\"
MTREWM,P>0K'AQH3937:+T=E3/]W$/35<I7*VEAS/%_!PL[]?F9,#MJ8TT@VH
M2VPZXZD4<^(H7,6W>N6"9VW=+F4)1\3&?,MS#HWCYXW9K-W@49G3\0*1JTU(
M78A96(1@6(G ZT.8=T!37FP:>;Q,\[Z%9(2W;JV98M./V%R>D)5F0#*>?7;+
M9K(V;L1:,(E,X522U5-/9NF19FGX@-YWHY E4WM M K8K<U:"HL89#6CHF:S
M__!P0-7 GXT6N.IZ$G/:@ =^%I WXJJXY%E??SHWT%TN%N(1H*KLV^B(DWHN
MCZE$VC-7#R4-T$]KX%"_T0XH\&=MQ+T6UF9E>O490ML;5NF;+5EW3#=@<#](
MK8UY3QV:JF6[56N>X!="&<,>EL<G4%FI32]%)8HG?5@.%],I\6S5HP:[K U4
MDF&(G*+DSF((]S -*6:.&@?B[,'B56/G#?N F)V&7%= "K.(IR+F,*U$W''3
M1V.:%ZM1)$%4Z:FKA]NC>O["C$_(XK$J/"CHE&-M5-8@3ZNH'W/;'6-KYBOB
MW>;N<W]92<ZTN&'X>7JO2:2[T/><8C2)O!+^P>LT^K5#ZDIB?*:8#SQX/[JV
MY_:E>PQR&#;=QM/>/W;O89 :YVY-#ZI%6/;:(/(<.HPM!DZ;AGXD:=NI]RN,
M(TW;##:6FV&#,@=:F*FCD_?2>2,66YRN]RWPZD5^,A7@Z&5 @Z5TOTJVQ "(
MQG">:U"LC(4T9[C%+$]L0[5*NMC8QOXQTV&[:L4!H5^VL&)[P@P3F3/#G#>)
MO1&<@>W#:MXSR+/JAA]W813)C-8]LI_$])&;HPON1B$&6W!8@E1L%V5U]/-)
MY!\K\I=TS-79X=4 Y;3N>*\/'M48UE[CL#0(.W-=7:)*#<O-"HVSY0LFS=YI
M\8W3 _>EE? DD>,#]=T2-MP+4W."X,X<7I#R+0B<A3PZG"VA"G-5@J"G9FPE
MBW.7)=B81VTT;]C8%-7]!F8!;J)[OM59@[^&,P])[YK; [[6'+#[U!SPU!SP
M7W1 \^COQ]<WQ^KZ>'!8I9';K8=NY*GU[9N7\JCUW<F#B(#*?N]"GOL7[ZAO
MW[MS_ZJ=!V_/42LNSVFWY/:<]7=D'EU__%&=7@R/K^U.J']K1G^5JOWG^M_%
MW-X;=;:<I&-B+&M6][_J+YZ8_35F7SZ097NS*O]9W8[L<BM//'\,SY="DC=+
M,8H+K^64].KHILZ/+HV%H,H<P-+QE'7CIQUZU X-;3F"6F!R6X)[GWB[!M[^
M6'JQ+J92UZG#=-OD(M$K3+RU07(S)N(&4YAG(]6M'&ZKT[/ ,:8J("49;(XT
M4CRX-VOT\1^!M$XOU,W5\>'IA]-#=75Y]?%L\.\OW_]W20,8>>4*O[^I9&^J
M_3QP8=+;+G[5%H!ZO!=)!BYX:YYG;B2J3B9Z@(.FF[5QAKVN&]EYS5DD'DQ;
MJD:4)M-<U\E#,==AS(OH0E_:$^T5<E*A,(>&@*<M=F[<D^<BZIGW3UX)&?(T
MD>U!Z*A9R&NVLM";"-:ML+L<Y"25/$HMG "Z!7!FG<IE AJKUW%]:W:SR4#F
M=D<D-<N7DB&H1M=?4I.3K2_)L T(WFT2!DOYN&^W20#%\7IS0\;7&R7L03;W
M";,K).*!H^B&+5TY\&K1"<U(9.\Q[W?W]_>[^R]?=U^]W-E1&^;?_(61\^.C
MS2<[_DC-/?/L:6:CN0.5SWBPKCZ@7/VV 926U7FS,[:CW(OSL7EL2;ODWI-$
M34OPBW=E?J:J1<F=5=K<G#6VQI]:ZO.G6_AC)90WB-7,7D1KSX/&2:7,]BH?
M!Z_N-1M#3!43%WDQ9FV113V>%;5=\-6;EJSZ^D!C7!KG2^UATJFY)Q]3Z'%H
MYG3#:ZDBUC4P5^"C<9)["-VA2/F5"RRFNGJB2CM6IX.7#D?7"E[=OEM3SH54
M2U3^-(P"<QC<#D*+8LZ&:W/.-IJ34&<3>,N;ZY%XTIM'>CSIML@0:\& VIH(
MZZCF6BGN8M7;%=O3XW9SI+QM9%W+K;*>5;"GO7CD7OS("Q%D+UR*RFS(I:G^
MF\O0:XOV4.[+70R\?*^V.QZS5!)=^%4*7C6@S55>+]T/]Q"83,RO3B01E+!7
M7[967^'N^NK"0&3"-20U,(@AW*3[*PH>G$1NBM#@M[3/ U8)-)?:%:_^2F)W
M-X6I4XB9F,,D3WCS[\(JG\3QD>)X8J^+-1<1TY/4]H%=Y[.9.<!OVY,:/YFU
M7'6?T;!/[PW7;FV<G&ZJC4,Q_%= 8VH@OU1F+SQ;^?M?G:K;PXOM=6?W2+E'
M@$W>.A+</;;&59:LA35_\$LDN#GL_04E@:F\GIPND/]>+F>S1:2E[PY9A5IR
M\A6HW1A\/-SD;6#2RU=U&JSB(X8U]U[7)#2SW7DY^J=I&O[*PMT]Q<L5Z"H"
MN!<;\,?'EG+U?W!<>V6N#<JU;MXX8AU3\^8#UV931D $5^9WZT;$":?U0VN_
M&6F86 39;E6GI^Z7,Z17BH>V5T<+]^.!"M_Q?A?S[=96E[\ZV=_:WY?30G=W
MO7'@\4ZS%P"7=U[A3[]VWG'W43F%Q_\FZZ/FNTG*C%7.K]ZBQA/P<HW:.F<^
M.'UW;2ZH"N[_<F3SMRK_E;?Q[CT5>W];2?/;A<T7_(5MN0=#?IG[_P!02P,$
M%     @ KSAQ6TZ&5ATJ P  ZPL  !$   !T;GAP+3(P,C4Q,3$W+GAS9+56
MVW+:,!!][TS_0?5KQC:&W""03$N&E@YI,I!DTKYTA"U C2PYDAR;?GTEV^)F
M($!;GN3=<\[N>G=EFE=I2, KX@(SVK(\IV(!1'T68#IN60\#^^.@W>U:X.KR
M_3N@?LT/M@TZ&)&@ :Z9;W?IB%V ;S!$#? 94<2A9/P"/$(2:POK8((X:+,P
M(D@BY<@C-<"I4X/ MG>0?40T8/RAWYW)3J2,1,-UDR1Q*'N%">//PO%9N)O@
M0$(9BYE:):T4O]WH-UCX,_+1J8B2L[2/GR8Q/8_;0^K=#&#X]6AX5T].@M\Q
M(I]D6)]^N2<OOZ;GT7?O,WP<]#N#\7'U^<?#;1ZR*?P)"B%0O:"B9>GZBO*2
MFL/XV*U6*I[[=-,;9#@K!S92@NGS.KA7K]?=S&N@)60ZY,1(UUSM'D*!9LK*
MB[?@,1424G\)'\@981%\XN;.)2A>"SW-H=A  [2"$\AWQNS550Z%KYX88"SL
M,831##R"8IB)%HXEL."R#%3&59 MIQ$2:Z&Y:XD@:3J/+QG%:32!/(1Z+#.@
MYWEG:K<("A&5'<;#:S2",5&YO,20X!%&@04DY&,D]9R)"/KH;4$SKY!2IL9:
MK59AT;8HPFIN9P9ETGUN<$;0O2H Z(/:JXU1M-]M,W4[6  '+2L_+N@9Q0"-
M,,59]&*5/&#KQ8EUL>J8,9ON*KBL% L4W-++[!QQ)!0]JZJG# 6_@&SG^I#X
M,3F(.L]O&[.PFW=9>LEFH_IH!+)-;.B9:5D"ZZO0*FP3CD8M2\^.;5KZ4Y7M
MJ)DR$!UARR9F/5I]4T5@(P&Y7U(IW11*A$6(2ZP&>^$ZR%/'4M/O%L( '4=8
MP/V'E1,XW+=R14'D/Y;<T_KE6ION\G*IY]4%;*IR&9> EI9YVW6:?PAZS,^D
MME#TDVUXMC;97M6N>4XJ@GFF^R0Q?P/[)6%X!R2QX5)?%U]L@NM#-D*[!MWP
M<=@:="W'140*8SDXA<5/R5_DD,GLE<12.P/)72VA18_MBJ>:N#F=MYC9LSAH
M"'P64\FG^PS"(L4\'-:-^9^ W1IA\'D3]/^"0\,>, 7EX.M&H.GF:NKX!U!+
M P04    " "O.'%;F&0V[OT*  !_A@  %0   '1N>' M,C R-3$Q,3=?;&%B
M+GAM;,V=76_CN!6&[POT/[#N30N,XXF#72#9R2XRGF1A;#9)8\]LVT6QH"7&
M$2*3 24G]K\O*8FR1/)(2HJ2G(L9C_@>ZJ7XF*2^CC_]M-NDZ(7P+&'T?'1\
M]'&$"(U8G-#U^>CK8GRQF,WG(Y3EF,8X992<CR@;_?3CG_^$Q)]/?QF/T55"
MTO@,?6'1>$X?V _H!F_(&?J94,)QSO@/Z!M.MW(+NTI2PM&,;9Y3DA-14.[X
M#'U_=(+1>#R@VF^$QHQ_O9_7U3[F^7-V-IF\OKX>4?:"7QE_RHXBMAE6X2+'
M^3:K:_NX^UC]*<,_I0E].I-_K7!&D#A<-#O;9<GY2.ZWVNWKR1'CZ\GTX\?C
MR3]_O5Y$CV2#QPF5ARTB(Q4E:['%'9^>GDZ*4B4UE+L53]4^3B;*3EVS*$TZ
M] TG67*6%?:N683SHM=[=X- A?S?6,G&<M/X>#H^.3[:9?%('?SB"'*6DGOR
M@(IFGN7[9T%2ED@01M6V1TX>[&92SB<R?D+)&N<DECLZE3LZ_E[NZ*_5YFN\
M(ND(2:7@ VS7::NN*FCBVNP=X0F++^G[7.O1GNR+[P[/_X<&-..=-V')<IR^
MRWPSTKGM&_*^(WZ(<W^DQ3!/WG>D&Y'_%]NY:?G-A]=^7%.Y\5I\:EDDNUQ,
M8"16)F45'2-PL8=B8JCJKFMG4:O>5([FC)MMES-C46=&HJ,U>YG$)!%U3[^3
M'\;R0]%L\9\_9DPL!"Y66<YQE*N:BF:<CRSE$]V25%YPY0OSJ*=QE6(2,3$U
M/>?CM#R,9?@#9QOK;JM6,TOA'^FJCB\/B]@%8+0EXR1C6QZ1-_5*TRUTE"I'
MFU0HY(J*T/'7Q>C'0H-^5ZK_?)H<:G'0T6()M-T0FB]%C986M(M==;/-E.KE
M9ED0G6PQI/>QDB"I<=S!%V+'L=SY58K7%OM:N:LNMMI2?=PJ#**3;8[T7JXU
M2(I\=?,7DD4\>9;+^:YVM&3..]UBTNC[AB8L!$QC, D-K:>!_9ZL$SFU2 OR
M_);(C1W#&*!W/?1WVM;G JLX"&B&. 1GBV80JJ,\<71!Z1:G]^29\2Y\VC+7
MU-A,ZK T-4$Q8C$&HE%J42GV1,0_MN*,G?!TWPN%H73-!6!51T.3!46'W1L(
M2"WWR\B28YHE<@#KA<24.C_= ,P:IQZ:+BA. '/P*4FM]TO*XI&DJ;P=@&G_
M@&(3NZ8%-JSS8BJ#(@:T!S)31* J)!QL+E_DZEPLDP8VMJ'W"8]ANXN?6APL
M0KK#@10584C&>2*I<1NBAR%#Z9H>P*K.C28+BAB[-Y"54HX*O7](+FD\")%:
MYP<0S:8=CTH4(!QM9WUH"+5/,*Z2+,)IZ>5*;,LZFF?1N@8$M*M#8@B# @5R
M!\)2!BAFBA"OP/R+8#X,EX;2#RR&53LJM2Q 4'1O?9A(O1=(9EO.6Z[A&0>6
M.KLIVV.VOC\+Z(( I<><<=>VE+= \30#7=(\R??R<;J;[69%N*5QIL05&Y Y
MQ81>'@0+@"F=@5*&I Z50B\]K^X2T%P^Q @V1Y>Y)<!NLDU!6Q,0"59C  T'
M;?%,J1<B9F)DXCB=TYCL?B%[L%V&SBT3@,TV%)HH("KLS@ L*C$JU$C(O8!Q
MQY,-YOM%$O5,%:;0+1J0T38;NBH@. !K !V5&BWF,Y\SR1+OYK$ -7E(RN?!
M>R@!]6YAZ;'=9@80!X1.MT. (!&$VE$^09K3B/%GUGC<8<:V8@#<SU@,KU!Z
MHMQ"-:@);;0Z0P(";(A/ +-6Z(?RF13$Y&L\105(UN"%N(LX%@<JJ_ZY3B@Y
M!MMOU;JEJ\-NFRF+,""28'< /Y7R@_J 9 RZI:% ,WU#4Z?^H9D.A68:-#33
M]T"S?&6!0'/RAJ:>^(?F9"@T)T%#<_(N:$3'>QUK9N+C+5^R5]O#V:#2"S*F
M52LP!UEXN!C>^F"1 7(](T-\8E(LK&[Y'6<O"8W@)3,D]P(,8-I*C:8-#QV[
MP3Y^Z@6QBO,ZUI2+\MXOB9+Y&67:)NU#3*D)#Y*VL=[!I53[1.*.93E._YT\
M=YZ(V\5>\+ :MD+24H:'BLU>'S!E#!)!/DZL*USE#0WKJV1:N;M7@"VV#J\
M-PJ#@,#FR'P%N+QZ4HI<=[-DE!,,C CM8F>=;#%5]W&C+(PN-@T9/5Q\KX7&
MQQ=99G=)[QX9A1\0,"6N>AHRIWI;+P^BQP%3>J\7,E3H/%V-EQDF,OOPW2AS
M-K/K=NJ)7!4$T;NZ&V.:5N6.>_,WGN1BSS.VV6QI=9?']MP@H'/5RYTV58];
M14'T?I<SG81*B]IBQU@L6)I$29[0]:_BY),GV-8JF\@5$+!!18.I" (%T);.
MP4&(E-(Q!'><2 B)Z(CB)4"96(C?/CQ89_LNL2LH^@TK.&!E$)#TVM-A$0'C
MJ!&!RA!4Q/C%9IYE6\+?!(\EQ!-"H'D )$,?(DZ0R5ZHRD"?;"U(M!7SX_YX
MNEHF>6H[N30ESN8DP%P](VGE0; !F-)9*,H0>T#'T[^M_HY4E./NOV%+CF7N
MV,5^LV(ID'W*JG(%08=%Q8%%$@0*L"^=AAN&*BDJM3ZR4[7,6IJCE;L"P&I+
M=7VK,(A.MSDROORMOO8TY%_NHD=AB@ O)-AEKH=^FTE]^&]J@D"@PYAQ4E))
MD=+Z>"'A,&6M^Q<!:V^+@'7/(F =XB)@/701L/:V"%"[+5.$B''I=I4F:PPD
M)^Q4NX:BP[+.AT4:%"JP/W#,J$/0(<9U1LLBQ9E,S\\WQ?ZOQ =+*P&=LYR6
M73;KI)8V41",=#DSTEJ62><:8B35KKG8QDE.XM+,54(QC1*<UND1;5?$^T.<
MT3+0? U.CSX,AH:9-' JPU0NPSKPD.K2]:7T\@&,WTB:_D+9*UT0G#%*XO):
MBNU.4;?>[1,S/;;;#\T XB!P&N(0>'1&!HV?9!128=65,"\D?6/IEN:8%^^2
M<]O(!.C<D@/8;!.CB0(BQ>X,(*06HU+MYP7M,GM$O<@J?W<(;" D=_RZ=J=I
M[:UMJS8@9CH-0N]P5SD_#FOC,LK3*Y8YD;\7D;R0+SC'E3>PO9#<]4N57:;U
MMREMVH 0ZC0(OC]9Q\A4,5@QY2UE#)^)I=::=3PEKJG<)XXQ+)JY8VI)0'C8
M?'5DD.%(:;VPL-C@-/V\S1)*,G@BTE1N6;!:;+/0D@3$@LT7P$(A14KKA87+
M#>%K,;W]S-EK_ECE9P7;!JC=LM%IN<V(51H0*UW^ &94""IC5$I=/_#L#@G%
MRRR+<$LM4L?8@&8U9@Q=2,! Y@Q:4A+)ZRTW+$=+AKYF!.6/!%U6/T/7S 1?
MUN/KET:B2+X04:[*:8RY#:$NL?-?'0$-&[\]8BB# *G7'OP[)'4$4B&.J;D5
M#//F>5QA8IZ3#?BV0W^(*X*&FE<<]>F#H&F@29VI(JQ]<ET$(AGI,YM1,[D]
MO,1KB1ROC"T&M85Q0Q$$(Z M:%G<_*T /[GSMJLTB:Y2AN&K+"V-XXQYICTM
M6=Y!$! !IBLH15XA1(722_]_QO2);Y_S:'_'642(?,HJJT>KONMO Z/=,O.F
M)K5I&A0:$&=O\0L0>*@"->KXT)BQ?%[,DP^-RVQN+'I:/&)Q &^W>29G4&$,
MO@K>&>3X]L* !F@W&3HB D)O@$WHAD,1B8K0#Z@,1HUH3^=GV2$+((D_[^_)
M ^'RO8,EV>6?Q8Z>.LXP!L2Z/GL;W!S]9*XW, @(W^H6.M7+4+,"M)+/B%55
MH-]E):BHQ?;[Y<U-U^*3V*PVB;]6."-BRW\!4$L#!!0    ( *\X<5MS$X%H
M7 <  -I7   5    =&YX<"TR,#(U,3$Q-U]P<F4N>&ULS9S?4]LX$,??;^;^
M!U_N.83 M3U2N ZDI),I!8[0]NY>.HJM)!ID*2/))/GO3[+C-#\L>7GQP@,$
M9R7M][.R[+4DGW]8ICQZIDHS*2Y:W:/C5D1%+!,FIA>MKZ/VY:@_'+8B;8A(
M")>"7K2$;'WXZ]=?(OMS_EN['0T8Y4DO^BCC]E!,Y/OHEJ2T%WVB@BIBI'H?
M?2,\<T?D@'&JHKY,YYP::K\H&NY%;X].2=1N ZK]1D4BU=>'X:;:F3%SW>MT
M%HO%D9#/9"'5DSZ*90JK<&2(R?2FMN/E\?JG*'[.F7CJN5]CHFED<0G=6VIV
MT7+MKIM=G!Y)->V<'!]W._]\N1G%,YJ2-A,.6TQ;92E72U6Y[MG962?_MC0]
ML%R.%2_;..V4[FQJMM^R@/V6)YKU=.[>C8R)R:->VTSDM7#_M4NSMCO4[IZT
M3[M'2YVT2O@Y024Y?:"3*)?9,ZNY[4F:N8[06A^;*3JY:!FQG-N*3MYTN]UW
MKIK?^]+VSU;D*K!AW[AKI&#+^8RHE+A@=]SWG;5M9Z?IN:*:"I.KO;$'=GR@
M2V-[%$U*+UPUH#;6E3#C[-==IANU7?_*4MN<_5A8KGTIO>$RWG& NSA(M4NA
M[-,Y;4WCHZE\[B24=1P9]R%'E..Q__S(&[H<:Z-(;,J:.!E3GM?_P]KLF70:
M\*HD\6AKK'9JUV+?I^VX7:HXDBJARK(NZR(JWHG68?=<6W3F1-F*VO&,\4V@
M)TJF/CIK$M+CZ#8HVT0S-"]M^XGS8<#)M!KGG@F09Q<#:*4:+*(?J8X5FSLN
M-6!W+(%\3U#Y5FAK&'-Y[CS0*7/^.E?<19>Z@^%QP5,$"/X4<Z0(JD6*P*40
M&>$/="Y5#?A=2R#O/S!Y5VE#POQW1I2ABJ\@I ^,@;#?8,+V*$3B_:B(T,SQ
M@0 _M 82?XMZX^'1B(1\-*.<NSR."% OK[('8G^'B=VO\Q6 OWYVUW=[:8&S
MWRH"Q/_G:\%_H!8I O=4,9G82[H"L#\P!E(_PZ3N48C*^UHD4-H;4W#^@P][
M3QX2Z@'3,>&%1P-[3(=Q5YA#D:/DG+4R4;'_2XD"0]\RAB)'24-K)#8,O)\I
MM>-,<%3Q6T.1HR2@=2(;9GXM##,K]^#_-DO'/Q^<[K(^M((R1DDZ?:)0V)9/
M&H1Q$QHAOON64,8HN69(' KGOM6C"!^*A"X_TU4(]($IE#1*CAF4AX+Z7K&4
MJ-6(Q?6#QJ$M%#9*9AD6B$+[D2R'B57%)JR8$JR'[BT"98^25H+DHH1@*&*I
MYG+K<7%?9O9\7/5E$AS2:PI"PX&2;[Y .DI0+I/$XM+K/S=,T&XH%)7FX#DB
MO  $9+X2["<OPWX"QXZ2A];*?"783U^&_12.'247K96)B;UO/]ZI1[GPS$![
MC:'(47+1&HF8P/,KS9VZ5_*9%2NCZJ@?E("B1TQ1PV)1.WQQD8?T]M(2RALQ
M7:T6A\GY7FI#^']L7G<G66T/98Z8N(:$-OV L8B[>VCA6TJT9P+EBY*K5LII
M&JF+L*+$WWUW+:! 41+0*C$-\[R1;NYC)D7P>>RA%90K2B;I$]7TP.O6$FOO
MJ;_U-7@%&\JPNB^C88S?%3/6@[Y,TTRLG]%X9L4\IE"\*.E?4%[#J$>2LY@9
M)J9?[!VB8H17<ZZR@T)&2?;\PAHF?*^HBS2UM]WY.BZWV4#=32:^D3=D#R6.
MDNO5"\4E/]0ZH^JE_"M*0:. DO9!13<]SM XL\/>JGLR?G0[9CRCS($5E#5*
MRN<3U3#;6_FHB-NP-UJE8\G]VT,J#:&$41*\@+2&(>_X48UWSP0*%B6SJY2#
M-"9<+^,9$5/J7[U0;0D%C)+IA<2AC;U3T-@[?>'8BY+Q^40AL2W6AMLSZF[,
MV93X=Y(%"X#WV6 2#TAM>O]>ON7'[>56:>['P'ZHQNXQA0+'V2(9DM<TZBQA
MAB:%2P,FB(AM2K79U^;)SNM+00. LX<2*!KE\?YWROEG(1=B1(F6@B;%K7[H
M";^W"#0*B'.(-7)10O!-\LQ24OE"4.4Y!SRF4.2(<X<>>3AK+XM%S9MK3_'2
MCA!Q7PDH>,1)Q+!8I/5IACJ?V3/]2 Q9>QCB[RL!Y8\XH1@6B[9^7O7MA6<J
MPW/F>X90VHA+82NEH4 >I83SJTPS075P;-DSA$)&7/-:*0T%\G5*U=0.:I^4
M7)C9>F]G"+:G !0ZXLK6H%0<^,N?^\B+_6]!\A76X+<3(&+WBL1Z[48<NX44
MQ95<)$1YJ(?LH=Q1-U;ZA39,_L[,J-J^?\J=&=J\+;3HH;X4- HHZ2I4-,ZU
M=6LG?_#2NF,'Y8V8F%8)P]DSE8TYBP=<DN!]^8X9E"]B%EHA"P7O%1%/*IN;
M>'6O9$RIFS[1F[,-D! !*X"&!#$_?1$*G,<%,DW=9B(9/XUF5K2^RTS^"E/K
M7_"A0; <-#28FS@!PI'N@O3/C5XTN5H]T E5;IG"(UV:*]O04_BF"% <&A_4
M-PJ!,52$Z;QSH.O&'G!OJ2V^<;_<FUCMD?\!4$L#!!0    ( *\X<5N-%>,2
ML14  .-J   2    =&YX<"TX:U\Q,3$W,C4N:'1M[3UI5^+*MM_Y%?6XZ]RC
MZ\H0!@4'WD+$;EI%&K2'\\55)(5$0Q)3"4/_^K=W50))"*BTV-WK7=<Y+215
MN_8\524>_^]T9) Q<[ANF2=_*]G\WX29JJ7IYOW)W_5>H]7Z^W]KJ>.A"\-@
MJ,E/TD/7M0]SN<EDDIT4LY9SGU.JU6INBF/2<M#A-'%<(9]7<M^N+GOJD(UH
M1C>Y2TV5S2<9NOFX&C[>G0_M.X8>&8I7@D6*N270<%=;3 @/WL_)FY&A;N+0
MLASJ!D-U;I4*RL$Z/.2(^83IJK$*X@P4LF^GW<O%<#=Y_&)HSG6HR0>6,Z(N
MB! AE3/Y0J:P'P*2X4R- (+OV7MK_"R<2J:H!'"6A!.E%&_W*9]S7&,Q=@=K
MP@V842@' SV>N:?4G@\>4-X78/T;\<&.93">.%K<B0Q7+<]TG5DR(O[-R 3N
MN,N@X6)DD&M.%^BZEJE/[2$%QF55:R0&*@J('*V&4:V6(OAS[.JNP6H-SW&8
MZ9(NLRW'/<[)JZGC$7,I08@9]N3IXY-TPS)=&)BYF=G 4E5^.TF[;.KFA*'E
M8%9.+G#\/YD,.=>9H1V2'G./2)N.V"&9:M,CTCH3'^[RA>;=;>^OPMF'>KT#
MOQ!-DLF\<'*Q>H=$W\6(O0N(?3FD4F4^:8/9Y>H= _T!_.&_^HB9&OSOGAOT
M_FY #<Y> >DT!*EI@AQF#0#E4*-E:FQZP69W>?!6I6*^F-]_.=C]4^#RV9UR
MYQN^A ^77@&B<-<##C-^5[@3;D["X.+:*\"<(28='U1Q":%5L/N6-B/<G1GL
M)#T M3LD2MYVR8T^@A%M-B%=:T3-/7EA#]9W] 'JNJ:/@VF:SFV#S@Z):9D,
M[^G30]14YH QB"^ZIC$3+0._P:BV-P(XJM3SJ=ME@Y-TG5\/4$,RBI)!#ZIK
M)^ESJKIY_"FFB0E$PUI,/XPH0KHF-.$X%X'\,VN5PFLEJDJZMM"5I(5S89H1
M#8<-&/@!E7%Q'WWG(1=!$= A(M(=#AW$#,TN$QA*=LJUM'_;!<=PDN;ZR#88
M.@-_F0ADN12W/,=?"08)L1_ZQ M"8\3[#BL8R03!P<7Y95W#&P.=.40@SA+C
M2Z-U$>5-?/)\L5S2:OY:-C#2TI90@ CON&?49;4%]@&<Q;WX+%"5%7.".S&4
MPJL'UWSV15CJF;KD)QA7G(DC1KGGL)IOA(<P)  5W(K 1UC)P*4]KX+O$R_&
M;+C PFG$%P$+!\$M,11G"F6GKN4L[KZ:]CAZ"3!#*YXQTQKIYC-K/LN/^*()
M8(/;8?+C;/1-;V%ITN1]GW><@[FU5"IU; <N<D2=>]T\)/ET[=__4O;S1\<Y
M&T:$/7O7,UBF0^]%4 N[5SDWXUJV],U'Q+_2MUS7&AV2(EZ;Z)H[Q 'YO]*1
MZ7W+ :SD]%.#JH^D /Z=6X:N'1'_9@!)WE<6]S$B9+C^ \(-7%T@CP3Z_X9(
MR$5HB##@I:$E(&Z957%0I5> .B)HOAEJZ/?P506OPQS@4K]VVV[=-,]([Z9^
MT^P%R_5KVURRUVS<=ELWK6:/U-MGI/FM\;'>_M DC>NKJU:OU[IN/XO':[BX
M$H^OE ^AZH,4;X^<91M94LB72]6MKKI6GMN%7GD+EIU?=Z_(,;>I*5PGYEW5
M_)E(+#.9,TOU,"G!#/Y.G2>]B_3WQQ,UGBIEJ_+AI@+@-LQ.JN'L)+QFNE;)
M7,2SD>,<8EO[=5)]$U4%@^DVVS>DV^Q<=V_^<&(ZGL,]"C6A:\$D%:MOHA2)
MY1"EO*/M$FM W"'#6YZCNSKCJ>94'5(3G&I==?&V4BV6_F0F8-:%=#BB*"8[
MFO^=48BQC+N$C;%FEK>9MGL(54HM;G;%F-EU1-K6E#E=LOVU#CJ32J>2'_7H
MJ^Q/=DE.TOK4/41<1S!VJ-'9#!!F9M0^E7R2?4:02]?:UIB-^I!**P=[!%?Z
MU6:[)7\9EUG%EYDLJKKL7N?8AG*QGDT6V?3+HWKU]+7]O='?V&4JRG)!%UT[
M7;NY;K>^D<['>O>JWFC>WK0:]<L>^7A]>=9J?X#0W.UDU\AHR_:RTYP"*8(&
M:38![H1RPFVF8FFE$1U8[7("O@*LQME]'^_@TK[!X)9A #=4["*GP0+PNTTU
M+?CNHQ#*4>>IIVH9!K4Y))C!)U&''+M.,&O,'%=7J1'@ 9FL7ZH<N]KKJ?.1
M*!8!!Q_'C*/?#V%Z.5O"5#JX:K#!XF*BB@O]#F&0&="1;LP.G\,AG%;G,:].
M,!8E8BPM4[4<\(>B6]MSP8TT9#NS86FKT@WN%0J%@V[_P\.F[@X;R5A;N\QV
MK#$JX)*_*RP;UUI<P?NQ,=7H6I?G?W2U-Y!SZ3>7<R$BYW/=8, 2" [)0NUK
MA8_[Q2N]75<V=XC%99DMUL4&CI(I[N>5ZKO)Z'>WQ:B,;NBTY7>T5*'CZP3F
M7I]^.O@Z&^U?;2ZOA([D"AS2M<)^1BD52P?E_ NE!_\XFWC<%\LKF+J5;'I'
M^!?,GJ\A:W;()TB:N::+M#I61V\/"0C*$9^W&UTYT4A^$_8UK-%(Y_P]N86N
MADAUW?T36-3J]DAS9!O6C#GOQJ2H<9.VE=V-9II1V\V)/*SV!Q:#"=YV/^)M
MZYKF,,[]7Y>ZR91D3_O]\:JB52OZIZO7E7<15UM>=K4)"*";)5<4,NZ>ZS#F
MKG"U>TO-HGH2:0WX>.W<6!,SF3#MX_AT-*SG/QX,-R=L?R5AB^73M<:0ND,Z
M>C$]2A(]PB5?.QU(&7537579];_16>G":W\:;#$[/5A)=0Q)3$LGY!-S.)N]
MF/I"$O4="U R_M'MU9GYZ,=IO_[Y\Y6JW&\NT,I*TB(80#IW4"U4?D6'8<?'
M!XM6VP$NZS8U")LRU7/U,=:RX-\8WR4[@"M!9-^I:'U[\(M^PK__52DH!T<<
MAAG,'EHF(Z:(=7M0H*N&A[&+4(?1E H$'Y(U_@\-LPXC5RO2A3Z\Z=-VXY3K
MFRM2I*,<7A,D6-DO[*Y0G25KJ/IH7UJ0.G:0\G5Y,?]6OGCXDC>-+YMW=@J1
M9EM\W73MH%K-5,K5]75,<O_K%2JAX'Y:/JX9#QZ'^#U#E\K41]'2I3;X*3 $
M3%C[UI3TF6%-B"[[O>?@UT@E<T$&N@$JDM(YZ(O+3(UIV"GF^L@S7&HRR^/&
MC'!("_A@)F;*"<3JP\(R6_!;R*%&D0=P'$+-67!O8!FP.,Y#WZEC LC)#F>,
M?& F<\!.6R;,]40BG:IG"UF)[N[A]CD65ZRRKUA?'=T%CF#*ZIE^9L23M<O:
M+]-_G'WCO/@Z#QMN]?8MRV#4%,=+8GH7Z2@FHH4>IWI0*AVMLAY_%F 3GD;L
MT.X [J:F2H6R+[WHKH#8#-A1#DCCO$L*Q7P6!NYNR<NME$P0_GN6H:N EGE_
M!<H-&FXDB^5;JW#[^&E8W9^^+I-YH5@BO:AEG)Z5R6(*<$+.61:(4J(9I1"2
M261[9BZ14CXK1[Z[4!J^4#H.0YW$PT%BCQ!]B7,]&*SRR)52YVG*/]H5=_/M
MD37"B32=5N/VK)!@:D8-S5UE02E?8$0I:9G"3G_W92*38]]=:*5DH;4X]YCS
MK.@^FX]*^_*Q0#]MW.I=)[K2&M$M8;@% 199IK2CODR _MC=[8>ID"^6D98Y
M$*O#V,^W=X7Z^9$7,#[\>;T*<$O7?K.-& GMD/23CA)MWA5>V?^-6=1;-(!O
M\)"VW)!6AT0U*.?KVMWA U9+5/LW_1;6JMO!^:LW8%KI5S'-H:*TZ<U&?<O8
MX;M_#LM^E9ZU_0U=H68L\&C@+R9#':XLG,I;M.M_DJO^?<F>G^#YK^!S/-:>
M!UFK=. SI= 7)I\<6\N#_HR7'XK?*VSS0C725HRO"S4B1$ +FXF6^KBR6'W6
MG+9O,;^#]/*^]'R'(_U-LNAFO%^^N/QB?2]OOEE:B#1.(XN"TVM_Z_Q77K%
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MH>)!5.;B"Y#H@QC80*XD>"I\P)O:^^L2*DP>%HP;49$0S%_AHJ7Z\M@9]E5
MV'$+]&.V9.E<I5$17)$S&?I(>#7,I/QD1HIA+\B;_*L4UL,3HRZ+WY'GXH*K
M*?^J;0 C8B,%;\=+  ))QZ_/]7+IAE2ZY<M",>*8\*'E&5I\\ 0O!M=0V!PX
M85 GS#%Q'9EK,G068\:EVT%W /GZB >:'A*0<!,,G81OB>+I:2ZR0<\)=:U
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M     &5X.3DM,#$N:'1M4$L! A0#%     @ KSAQ6TZ&5ATJ P  ZPL  !$
M             ( !H!\  '1N>' M,C R-3$Q,3<N>'-D4$L! A0#%     @
MKSAQ6YAD-N[]"@  ?X8  !4              ( !^2(  '1N>' M,C R-3$Q
M,3=?;&%B+GAM;%!+ 0(4 Q0    ( *\X<5MS$X%H7 <  -I7   5
M      "  2DN  !T;GAP+3(P,C4Q,3$W7W!R92YX;6Q02P$"% ,4    " "O
M.'%;C17C$K$5  #C:@  $@              @ &X-0  =&YX<"TX:U\Q,3$W
<,C4N:'1M4$L%!@     %  4 /@$  )E+      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>tnxp-8k_111725_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="tnxp-20251117.xsd" xlink:type="simple"/>
    <context id="AsOf2025-11-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001430306</identifier>
        </entity>
        <period>
            <startDate>2025-11-17</startDate>
            <endDate>2025-11-17</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-11-17" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-11-17" id="Fact000004">0001430306</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-11-17" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-11-17" id="Fact000010">2025-11-17</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-11-17" id="Fact000011">TONIX PHARMACEUTICALS HOLDING CORP.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-11-17" id="Fact000012">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-11-17" id="Fact000013">001-36019</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-11-17" id="Fact000014">26-1434750</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-11-17" id="Fact000015">26 Main Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-11-17" id="Fact000016">Chatham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-11-17" id="Fact000017">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-11-17" id="Fact000018">07928</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-11-17" id="Fact000019">(862)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-11-17" id="Fact000020">799-8599</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-11-17" id="Fact000021">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-11-17" id="Fact000022">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-11-17" id="Fact000023">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-11-17" id="Fact000024">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-11-17" id="Fact000025">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-11-17" id="Fact000026">TNXP</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-11-17" id="Fact000027">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-11-17" id="Fact000028">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
